Cargando…

Skeletal responses to romosozumab after 12 months of denosumab

Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects of romosozumab after 12 months of denosumab in postmenopausal...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClung, Michael R., Bolognese, Michael A., Brown, Jacques P., Reginster, Jean‐Yves, Langdahl, Bente L., Shi, Yifei, Timoshanko, Jen, Libanati, Cesar, Chines, Arkadi, Oates, Mary K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260819/ https://www.ncbi.nlm.nih.gov/pubmed/34258507 http://dx.doi.org/10.1002/jbm4.10512

Ejemplares similares

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
por: McClung, M. R., et al.
Publicado: (2020)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab
por: Chotiyarnwong, Pojchong, et al.
Publicado: (2020)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
por: Brown, Jacques P., et al.
Publicado: (2021)

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
por: Poole, Kenneth ES, et al.
Publicado: (2021)

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
por: Miyauchi, Akimitsu, et al.
Publicado: (2019)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
por: Schemitsch, Emil H., et al.
Publicado: (2020)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Two Cases of Frontal Variation of Idiopathic Calvarial Thinning—Therapeutic Effect of Denosumab and Romosozumab
por: Baek, Seungjin, et al.
Publicado: (2023)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

Romosozumab for osteoporosis
Publicado: (2021)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
por: Dempster, David W, et al.
Publicado: (2020)

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
por: Broadwell, Aaron, et al.
Publicado: (2020)

Total Hip Bone Mineral Density as an Indicator of Fracture Risk in Bisphosphonate‐Treated Patients in a Real‐World Setting
por: Banefelt, Jonas, et al.
Publicado: (2021)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Preparing the Leaders of Tomorrow: Learnings from a Two-Year Community of Practice in Fragility Fractures
por: Murray, Suzanne, et al.
Publicado: (2022)

Updated trabecular bone score accounting for the soft tissue thickness (TBS(TT)) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis
por: Hans, Didier, et al.
Publicado: (2022)

Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2023)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_krad1h1ibkngrobknlojr5jens